Pseudoephedrine

Introduction Overview

Generic Name

pseudoephedrine

Brand Name

Chlor Trimeton Nasal Decongestant, Contac Cold, Drixoral Decongestant Non-Drowsy, Elixsure Decongestant, Entex, Genaphed, Kid Kare Drops, Nasofed, Seudotabs, Silfedrine, Sudafed, Sudafed 12-Hour, Sudafed 24-Hour, Sudafed Children's Nasal Decongestant, Sudodrin, SudoGest, SudoGest 12 Hour, Suphedrin, Triaminic Softchews Allergy Congestion, Unifed

Dosage Form

Oral tablets (immediate release and sustained release), oral sustained release suspensions, oral liquids, softchews, drops

Drug Class

Decongestants

Pharmacokinetics

Absorption: Pseudoephedrine is well absorbed following oral administration, with peak plasma concentrations typically reached within 1 to 2 hours for immediate-release formulations. Sustained-release preparations exhibit delayed absorption, providing a prolonged plasma concentration profile over 12 hours. The oral bioavailability is high due to minimal first-pass metabolism, facilitating consistent systemic exposure. Factors such as gastric emptying time and pH can affect absorption, but clinically significant variability is low.

Distribution: After absorption, pseudoephedrine distributes widely throughout body tissues and fluids. It crosses the blood-brain barrier to a limited extent, which is responsible for some central nervous system stimulating effects. The volume of distribution approximates 2-3 L/kg, indicating extensive tissue penetration. It does not accumulate significantly in fatty tissue due to its hydrophilic nature. Pseudoephedrine is minimally bound to plasma proteins, facilitating free systemic activity.

Metabolism: Pseudoephedrine undergoes limited hepatic metabolism. The majority of the drug is excreted unchanged in the urine. Minor metabolic pathways involve N-demethylation and aromatic hydroxylation, but these play a negligible role in clearance. Hepatic enzyme polymorphisms have minimal clinical impact on pharmacokinetics. Consequently, liver impairment has little effect on drug metabolism and dose adjustment is usually unnecessary.

Elimination: The primary route of elimination for pseudoephedrine is renal excretion of unchanged drug, accounting for approximately 43-96% of the administered dose. Renal clearance is influenced by urinary pH; acidic urine increases ionization and reduces reabsorption, enhancing excretion, whereas alkaline urine prolongs elimination half-life. The elimination half-life ranges between 5 to 8 hours but may be prolonged in patients with renal insufficiency. Dose adjustments based on renal function are critical to avoid accumulation and toxicity. The drug is effectively removed by hemodialysis.

Dosage Forms

Available Dosage Forms:
- Oral immediate-release tablets of 30 mg and 60 mg
- Oral sustained-release tablets of 120 mg
- Sustained-release oral suspensions with concentrations ranging from 45 mg to 100 mg per dose
- Oral liquids and drops available as part of pediatric formulations
- Softchews, such as Triaminic Softchews Allergy Congestion
- Drops, including Kid Kare Drops

Dosages for Adults and Adolescents:
- Immediate release: 30 to 60 mg orally every 4 to 6 hours as needed
- Sustained release tablets: 120 mg orally every 12 hours as needed
- Sustained release suspension: 45 to 100 mg every 12 hours as needed
- Maximum daily dose in adults and adolescents: 240 mg per day

Specific Patient Populations:
- Pediatric (2 to 5 years): immediate-release 15 mg every 6 hours; sustained-release suspension 12.5 to 25 mg every 12 hours; maximum daily dose 60 mg
- Pediatric (6 to 12 years): immediate-release 30 mg every 6 hours; sustained-release suspension 25 to 50 mg every 12 hours; maximum daily dose 120 mg
- Pediatric (>12 years) doses align with adult regimens
- Use in children younger than 4 years is contraindicated due to serious safety concerns
- Dose adjustment may be necessary in patients with renal impairment due to prolonged half-life

Mechanism Of Action

Pseudoephedrine exerts its therapeutic effects primarily through adrenergic receptor stimulation, acting as a sympathomimetic agent. It predominantly stimulates alpha-adrenergic receptors located in the smooth muscle of nasal mucosal blood vessels, causing vasoconstriction. This vasoconstriction reduces blood flow into the engorged nasal membranes, thereby decreasing swelling and congestion.

At the molecular level, pseudoephedrine induces the release of norepinephrine from presynaptic storage vesicles, increasing synaptic concentrations which activate postsynaptic adrenergic receptors. This indirect mechanism contributes to enhanced vasoconstrictive effects and mild central nervous system stimulation.

Cellularly, activation of alpha-1 adrenergic receptors triggers a cascade involving Gq protein-mediated activation of phospholipase C, increasing intracellular inositol triphosphate (IP3) and diacylglycerol (DAG). This leads to the release of intracellular calcium stores, causing smooth muscle contraction and vessel constriction.

Clinically, by reducing nasal mucosal edema and congestion, pseudoephedrine facilitates improved airflow and drainage of the sinuses and eustachian tubes, alleviating symptoms of upper respiratory tract congestion. Compared to direct sympathomimetics like phenylephrine, pseudoephedrine's indirect action via norepinephrine release may contribute to its superior oral decongestant efficacy, supported by clinical trials demonstrating its effectiveness in improving nasal patency.

Pharmacological Actions

Stimulates alpha-adrenergic receptors causing vasoconstriction of nasal mucosal vessels
Induces release of norepinephrine leading to indirect sympathomimetic activity
Reduces nasal and sinus mucosal edema and inflammation
Improves nasal airway patency and sinus drainage
Relieves eustachian tube congestion to alleviate ear pressure
Exerts mild central nervous system stimulant effects
Produces nasal decongestant effects without significant antihistamine properties
Has prolonged action in sustained-release formulations supporting twice-daily dosing
Demonstrates effectiveness in both adult and pediatric populations with consider dosing
Minimal hepatic metabolism reduces potential for hepatic drug interactions
Renal excretion allows for predictable elimination in patients with normal renal function
Crosses blood-brain barrier minimally, conferring limited CNS stimulation
Does not possess analgesic or antipyretic effects
Exhibits minimal dependency or abuse potential compared to other sympathomimetics
Can transiently increase blood pressure due to systemic vasoconstriction

Therapeutic Or Clinical Uses

Treatment of nasal and sinus congestion caused by common cold, hay fever, or upper respiratory allergies
Alleviation of eustachian tube congestion to relieve ear pressure and discomfort
Symptomatic relief of sinus pressure and congestion in acute rhinitis
Used as a supportive agent to reduce nasal stuffiness facilitating breathing
Combination component in multipurpose cold and allergy medications for synergistic relief
Off-label use to improve nasal airflow prior to diagnostic procedures or surgery
Adjunctive therapy in allergic rhinitis where congestion predominates
Management of nasal congestion associated with sinusitis
Short-term management of upper respiratory tract congestion, not intended for prolonged use beyond 7 days
Symptomatic relief enabling improved sleep quality in patients with nasal obstruction
Potential use in pediatric populations for congestion with appropriately adjusted dosing
Interim relief in patients awaiting further diagnostic evaluation of chronic nasal symptoms
Reduction of mucosal swelling before performing nasotracheal intubation or endoscopy
Used cautiously in patients with blood pressure concerns to balance decongestion and cardiovascular risk
Treatment choice preferred over topical nasal decongestants when longer systemic effect is desired

Side Or Adverse Effects

Insomnia or difficulty sleeping due to central nervous system stimulation
Nervousness, restlessness, or anxiety especially in sensitive individuals or children
Elevation of blood pressure and palpitations potentially hazardous in hypertensive patients
Tachycardia or irregular heartbeat in predisposed individuals
Nausea or gastrointestinal discomfort after oral administration
Dry mouth or thirst as a result of sympathomimetic effects
Headache possibly related to vasoconstriction or CNS stimulation
Mild dizziness or lightheadedness particularly with higher doses
Skin rash, itching, or hypersensitivity reactions including urticaria
Rare but serious allergic reactions such as facial swelling, difficulty breathing (angioedema)
Easy bruising or bleeding, unusual weakness as a potential warning sign of severe adverse event
Increased anxiety or agitation notably in children and elderly
Tinnitus or ringing in the ears in cases of overdose or prolonged use
Potential for misuse leading to overdose symptoms including restlessness and nervousness
Rebound congestion or worsening nasal obstruction with chronic use beyond recommended durations

Precautions

Do not administer to children under 4 years due to risk of fatal respiratory events
Use cautiously in patients with hypertension or cardiovascular disease due to risk of elevated blood pressure
Inform physician of all concomitant medications to avoid drug interactions particularly with MAO inhibitors
Avoid use in patients with hyperthyroidism as pseudoephedrine may exacerbate condition
Monitor blood pressure regularly during treatment in hypertensive patients
Use with caution in patients with diabetes, as sympathomimetic effects may influence glucose metabolism
Pregnancy category C; use only if clearly needed after risk-benefit assessment
Breastfeeding women should avoid use or consult healthcare provider due to potential infant exposure
Avoid concurrent use with other stimulants including caffeine, diet pills, and ADHD medications
Patients with phenylketonuria (PKU) should confirm absence of phenylalanine in liquid formulations
Do not exceed recommended dose or duration (not more than 7 consecutive days) to avoid adverse effects
Alert surgeon if pseudoephedrine has been used prior to surgical procedures due to cardiovascular effects
Use cautiously in elderly patients who may be more susceptible to stimulant side effects
Avoid use in patients with known hypersensitivity to pseudoephedrine or related sympathomimetics
Avoid use in individuals with a history of drug abuse or dependency

Warnings

Contraindicated in children younger than 4 years due to risk of fatal overdose
Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation is contraindicated due to risk of hypertensive crisis and severe adverse reactions
Risk of dangerously high blood pressure, seizures, and cardiac arrhythmias with overdose or sensitive individuals
Premature or prolonged use can cause rebound nasal congestion or rhinitis medicamentosa
Use with extreme caution in patients with severe hypertension, coronary artery disease, or arrhythmias
Not recommended during pregnancy unless benefits outweigh risks; consult healthcare provider
May cause CNS stimulation leading to anxiety, nervousness, insomnia—limit use in patients with anxiety disorders
Potential for abuse as a stimulant, though lower than other sympathomimetics
Do not combine with other decongestants or stimulants without medical supervision to avoid additive effects
Use caution in patients with glaucoma or bladder neck obstruction due to potential exacerbation of symptoms
Risk of serious allergic reactions including anaphylaxis
If seizures occur, discontinue use and seek emergency care immediately
Should not be used for more than 7 continuous days without medical evaluation
Ensure accurate dosing especially in pediatric patients to prevent toxicity
Overdose requires immediate medical attention due to risk of life-threatening adverse effects

Contraindication

Known hypersensitivity to pseudoephedrine or other sympathomimetic amines
Use within 14 days following the discontinuation of monoamine oxidase inhibitors (MAOIs)
Children younger than 4 years of age due to increased risk of severe adverse effects
Patients with severe hypertension or severe coronary artery disease
Patients with concurrent use of other sympathomimetic drugs or stimulants without medical supervision
History of hypersensitivity or allergic reaction to decongestants
Individuals with pheochromocytoma due to risk of hypertensive crisis
Patients with severe urinary retention or bladder neck obstruction where sympathomimetics may exacerbate
Use contraindicated in patients with glaucoma where increased intraocular pressure risk exists
Patients with known sensitivity to excipients in the formulation
Patients who are pregnant or breastfeeding without physician consultation
Use contraindicated with caution in patients with hyperthyroidism due to risk of exacerbation

Drug Interactions

Contraindicated with monoamine oxidase inhibitors (MAOIs) such as phenelzine, tranylcypromine, selegiline due to risk of hypertensive crisis
May reduce efficacy of beta blockers (e.g., atenolol, metoprolol) due to vasoconstrictive effects opposing beta blockade
Enhanced hypertensive effects when used with other sympathomimetic agents or stimulants including caffeine and ADHD medications
Potential increased risk of cardiac arrhythmias when combined with tricyclic antidepressants (e.g., amitriptyline, doxepin)
Co-administration with other decongestants may lead to additive sympathomimetic effects and toxicity
Possible interaction with antihypertensive agents requiring monitoring and possible dose adjustment
May increase blood glucose levels, necessitating adjustments in antidiabetic therapy
Enhanced central nervous system stimulation with concomitant use of CNS stimulants
Potential reduction in effectiveness of antihypertensive medications due to vasoconstriction
Concurrent use with other cold or allergy products containing pseudoephedrine increases risk of overdose
May potentiate adverse cardiovascular effects when combined with digoxin or other cardiac glycosides
Use caution with MAOI-like antibiotics such as furazolidone
Interactions with antipsychotic medications may exacerbate CNS side effects
Concurrent use with lithium may alter electrolyte balance and requires monitoring
Drug interactions require thorough medication history and patient counseling

Preparations Of The Drug

Immediate-release oral tablets available in 30 mg and 60 mg strengths
Sustained-release oral tablets formulated as 120 mg doses for twice daily administration
Sustained-release oral suspensions with titratable doses ranging from 45 to 100 mg per dose, commonly used in pediatric patients
Oral liquid formulations including drops like Kid Kare Drops, designed for pediatric dosing
Softchew tablets such as Triaminic Softchews designed for ease of administration and palatability
Combination products with antihistamines or analgesics marketed under brand names like Sudafed Congestion and Contac Cold
Non-drowsy formulations for daytime use to prevent sedation
Extended-release formulations provide prolonged symptom control for up to 12 or 24 hours
Pediatric formulations include dosing devices such as calibrated measuring spoons and droppers for accurate administration
Over-the-counter availability with restrictions on purchase quantity due to regulatory controls aimed at preventing misuse
Liquid formulations may contain artificial sweeteners; phenylalanine content must be considered in patients with PKU
Packaging designed for both adult and pediatric dosing with clear labeling and usage instructions
Combination syrups often include cough suppressants or expectorants alongside pseudoephedrine
Strict adherence to storage instructions to maintain stability: keep at room temperature away from moisture and heat
Brand and generic formulations widely available in pharmacies with various flavor profiles for oral liquids